FibroBiologics (FBLG) general counsel purchases 40,000 shares in open market

Rhea-AI Filing Summary

FibroBiologics, Inc. General Counsel Ruben A. Garcia bought 40,000 shares of common stock in an open-market purchase on February 27, 2026 at a weighted average price of $0.3264 per share. After this transaction, he directly owns 180,000 shares. The filing notes individual trade prices ranged from $0.3221 to $0.3268.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GARCIA RUBEN A

(Last) (First) (Middle)

C/O FIBROBIOLOGICS, INC.

455 E. MEDICAL CENTER BLVD., SUITE 300

(Street)

HOUSTON, TX 77598

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FibroBiologics, Inc. [ FBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		P		40,000	A	$0.3264(1)	180,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3221 to $0.3268 on February 27, 2026. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

	/s/ Ruben A. Garcia	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did FibroBiologics (FBLG) report in this Form 4?

FibroBiologics reported an insider purchase by its General Counsel, Ruben A. Garcia, who acquired 40,000 shares of common stock in an open-market transaction. The filing classifies the move as a direct ownership purchase of the company’s common stock.

How many FibroBiologics (FBLG) shares did Ruben A. Garcia buy and at what price?

Ruben A. Garcia bought 40,000 FibroBiologics common shares at a weighted average price of $0.3264 per share. The Form 4 notes multiple trades executed that day within a price range between $0.3221 and $0.3268 per share.

What is Ruben A. Garcia’s total FibroBiologics (FBLG) ownership after this Form 4 transaction?

Following this open-market purchase, Ruben A. Garcia directly owns 180,000 shares of FibroBiologics common stock. The Form 4 specifies that this total reflects his direct holdings immediately after the 40,000-share acquisition reported for February 27, 2026.

What do the pricing footnotes in the FibroBiologics (FBLG) Form 4 explain?

The footnotes explain that the reported $0.3264 price is a weighted average across multiple trades. Individual purchases on February 27, 2026, were executed at prices ranging from $0.3221 to $0.3268, and detailed breakdowns are available upon request from the reporting person.

Was the FibroBiologics (FBLG) Form 4 transaction a buy or a sell?

The Form 4 records a buy transaction. It identifies the code “P” for a purchase and describes the activity as an open-market purchase, with 40,000 shares of FibroBiologics common stock acquired directly by General Counsel Ruben A. Garcia on February 27, 2026.